// App-Quantinova.ai

627 : Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy

Researchers

Presenter

  • Mark Lythgoe

Principal Investigators

  • Benjamin Mullish

  • Adam Frampton

  • Paola Dama

  • Emily Pickford

  • Laura Tookman

  • Paula Cunnea

  • Christina Fotopoulou

  • Ian Jeffery

  • Gayle Fyvie

  • Alexander Stevenson

  • Jonathan Krell

Medical Centers

  • University of Surrey, Guildford, Surrey, UK

  • D pharma plc, Leeds, UK

  • University of Sussex, Brighton, UK

  • Imperial College London, London, NY

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT03934827

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved